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Summary
Purpose: This study evaluated the association between polymorphisms in the estrogen receptor (ER) alpha gene (ESR1) and prevalent and
incident radiographic hip osteoarthritis (RHOA) in a large, well-deﬁned prospective cohort of elderly Caucasian women.
Methods: Prevalent and incident RHOA was evaluated from all available pelvis X-rays obtained from the Study of Osteoporotic Fractures at
baseline and after a mean of 8.3 years. Evaluable DNA samples were available from 4746 of these subjects. RHOA cases were deﬁned by
published methods. The ESR1 polymorphisms at intron I (Pvu II for a T/C substitution and Xba I for an A/G substitution) were genotyped in the
context of a multiplex polymerase chain reaction (PCR) ampliﬁcation followed by allele-speciﬁc single nucleotide polymorphism (SNP) detec-
tion with immobilized oligonucleotide probes in linear arrays. Multiple logistic regression was performed to estimate odds ratios (ORs) and 95%
conﬁdence intervals (95% CI) associated with the T/C and A/G polymorphisms.
Results: RHOA was present in 12.1% of subjects, of whom 325 had joint space narrowing (JSN) score 3 and 130 had an osteophyte score
2 and JSN score 2. There was a signiﬁcant reduction in the odds of prevalent RHOA for individuals with the C/C compared to T/T genotype
at the Pvu II site with an OR of 0.71 (95% CI: 0.55e0.92) (P¼ 0.01). Adjustments for age, weight, height, hip Bone mineral density (BMD) and
estrogen use did not alter the relationship between the C/C genotype and reduced risk of RHOA, with an OR of 0.71 (95% CI: 0.54e0.94)
(P¼ 0.01). The risk of incident RHOA was reduced for the Pvu II C/C compared to the T/T genotype (P¼ 0.11). Also, the reduced risk of in-
cident RHOA in C/C subjects varied by estrogen use. There was no association between the Xba I G/G or G/A genotypes and RHOA with OR
of 0.82 (95% CI: 0.61e1.10) (P¼ 0.19) compared to women with A/A genotype.
Conclusions: We conclude that the C/C genotype of the ER alpha Pvu II polymorphism was associated with a modestly reduced risk of prev-
alent and incident RHOA in elderly Caucasian women. Additional work is required to understand how the intron I ESR1 polymorphism may
alter joint degeneration.
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SocietyIntroduction
Osteoarthritis (OA) of the hip is a common disease. It in-
creases with age among the elderly population in the United
States and accounts for a signiﬁcant portion of health care
burden1.
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Received 2 October 2006; revision accepted 19 February 2007.972Multiple risk factors including age, obesity, tissue injury,
and gender, among others, have been well established for
hip OA1. With further investigation, genetics appears to be
playing an increasingly larger role in the etiopathogenesis
of hip OA2,3.
Estrogen receptors (ERs) are known to be associated
with disease of bone and articular cartilage. The ER has
two isoforms, alpha and beta. The ER alpha gene (ESR1)
is an important mediator of signal transduction, and this pro-
tein is expressed in cells of the musculoskeletal system
including bone cells and chondrocytes4. Epidemiology stud-
ies have shown that women treated with hormone replace-
ment therapy have a reduced risk of hip OA and hand
OA5e10 but other studies have found short-term estrogen
replacement may increase the risk of hand and hip
OA11e14. The investigators speculated that long-term estro-
gen use was protective of articular cartilage loss or pre-
vented increased bone remodeling around the joint5e10.
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and knee and hip OA have varied. While some investigators
have reported an increased risk of OA of the knee and gen-
eralized OA associated with ESR1 polymorphisms10,15e17,
others have not18,19. The mechanism for this increased
risk of OA and the ESR1 polymorphism is not known;
however, it could be through its effects of bone or articular
cartilage metabolism18. However, reports of ESR1 polymor-
phisms and bone metabolism are conﬂicting with one study
reporting increased odds of bone loss and a lower hip bone
mineral density (BMD) over time in individuals with an in-
tronic ESR1 minor allele polymorphism (Pvu II) compared
to a control group20, while another study failed to ﬁnd an as-
sociation21. The purpose of this study was to further evalu-
ate the association between the two widely studied
polymorphisms in intron I of the ESR1 (Pvu II and Xba I)
with prevalent and incident radiographic hip OA (RHOA)
in a large population of elderly Caucasian women from
the Study of Osteoporotic Fractures (SOF).
Patients and methods
STUDY POPULATION
All subjects were participants in the SOF, a multi-center
cohort study initiated in 1986 to determine risk factors for
osteoporotic fractures in elderly women6,22. Participants
were all aged 65 and older at baseline and were recruited
from population-based listings at four clinical centers inthe United States. Exclusion criteria for the parent study,
SOF, included bilateral hip replacement and an inability to
walk unassisted; African-American women were excluded
because of their low risk of hip fracture. The study was ap-
proved by the Institutional Review Board at each of the in-
stitutions involved, and all subjects provided written
informed consent at enrollment and each clinical
examination22,23.
Buffy coat specimens were collected from a total of 6975
participants at either visit 2 (between 1989 and 1990) or visit
6 (between 1997 and 1998), and genotyping was performed
in all women who provided adequate consent for genetic
studies (Fig. 1). Bilateral supine AeP pelvic radiographs
were obtained at baseline and at visit 5 (mean of 8.3 years
of follow-up)24.
The present analysis utilized the visit 5 radiographs to
evaluate prevalent RHOA and both the baseline and
follow-up radiographs to evaluate incident RHOA.
ER ALPHA GENOTYPING
The ESR1 polymorphisms were genotyped in the context
of a multiplex polymerase chain reaction (PCR) ampliﬁca-
tion followed by allele-speciﬁc single nucleotide polymor-
phism (SNP) detection with immobilized oligonucleotide
probes in linear arrays, as previously described19,20.
Primers were modiﬁed at the 50 phosphate by conjugation
with biotin. Puriﬁed human genomic DNA (10e50 ng) was
ampliﬁed in a reaction volume of 50 ml with AmpliTaq9704 subjects satisfied SOF entry
criteria and enrolled 
6975 subjects with available and
sufficient DNA 
DNA consent and
buffy coat collected 
Subjects with both
Visit 1 and Visit 5
pelvis radiographs* 
4746 subjects with available ER
alpha genotype and Visit 1 and Visit
5 pelvis x-ray readings 
RHOA case criteria (worst hip):
• MJS     1.5mm 
• Summary grade     3 
radiographic features 
or
• Definite osteophytes and 
JSN both grade     2 
569 subjects satisfied RHOA
case criteria 
4175 controls
325 RHOA cases had JSN
grade 3 
130  RHOA cases with any 
osteophyte    grade 2, JSN    2 
Fig. 1. Flow sheet of study subjects. *Study subjects were excluded if they had Paget’s disease, bilateral hip replacements, or rheumatoid
arthritis. If a patient has bilateral RHOA, the most diseased hip was used in this analysis.
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9600 thermal cycler (PE Biosystems, Foster City, CA)
with the following cycling proﬁle: an initial hold at 94C for
7 min, then 33 two-step ampliﬁcation cycles of 15 s at
95C for denaturation and 60 s at 60C for annealing/exten-
sion, and a ﬁnal 5-min product extension step at 68C.
Chromogenic detection of allelic variants following stringent
hybridization of the biotinylated PCR products to the immo-
bilized sequence-speciﬁc probes was performed on a Proﬁ-
blot II T24 (Tecan, Research Triangle Park, NC). RMS in-
house software was used to scan the linear arrays on an
Epson Perfection 1670 scanner (Epson, Long Beach, CA)
and to assign genotypes. Three thousand one hundred
and eighty-two samples were genotyped for ER alpha Pvu
II twice and 188 for Xba I twice. The agreement between
the duplicate genotyping was greater than 95%23,24.
RADIOGRAPHIC ASSESSMENTS
Prevalent RHOA
Details of radiographic scoring methods for hip OA have
been previously described9,18. Subjects were considered to
have prevalent RHOA at visit 5 if they satisﬁed at least one
of the following three criteria: joint space narrowing (JSN)
grade  3 (range 0e4) which was equivalent to a minimal
joint space measurement of 1.5 mm or less at either the me-
dial or lateral joint space, a summary grade 3 (3 of ﬁve
individual radiographic features), or both deﬁnite (grade 2)
osteophytes (range 0e3) and JSN (range 0e4) in the same
hip. For the present study, subjects with a diagnosis of
rheumatoid arthritis, Paget’s disease of bone, or bilateral
hip replacements were excluded from this analysis18,24,25.
In this study, 32 subjects had unilateral THRs and for these
subjects we used the contralateral hip (non-THR hip) to
deﬁne RHOA from the visit 5 radiograph23,24. For each sub-
ject, the worst RHOA hip was used in this analysis.
In addition, we further characterized the radiographic
phenotype of the RHOA subjects into those with JSN score
3 (n¼ 325) and those RHOA cases (n¼ 130) that had
a femoral osteophyte grade 2 with JSN 2 to try to further
assess RHOA by phenotype (Fig. 1)23. Reproducibility was
good with kappa scores for inter-rater reliability of 0.66 for
deﬁnite JSN (2), 0.71 for deﬁnite osteophytes, and 0.65
for summary grades 2. The intraclass correlation coefﬁ-
cient was 0.85 for the continuous measurement of minimal
joint space6,23,24.
Incident RHOA
A hip without baseline RHOA was eligible to develop
RHOA at the follow-up visit. A hip was deﬁned as having
developed RHOA (incident disease) if any of the three ﬁnd-
ings were present at the 8.3-year follow-up visit in a hip free
of all of these ﬁndings at baseline, (1) summary grade 2,
(2) lateral JSN grade 2 or medial JSN grade 3, or (3) def-
inite osteophytes 2 in any location and deﬁnite JSN 2 in
any location26,27.
COVARIATE ASSESSMENT
All study participants completed a self-administered ques-
tionnaire at the baseline and follow-up visits that included
age, northern European ancestry, self-reported health status,
age at menopause, current medication use including current
estrogen replacement therapy (ERT), multivitamins, other
supplements, and current smoking history. Data presented
for study subject characteristics are from visit 5. Height wasmeasured using a wall-mounted Harpenden statiometer (Hol-
tain, Dyfed, UK) and weight was measured with a balance
beam scale; methods have been previously described6,26,27.
Protocols for BMD measurements of the hip were performed
using dual-energy absorptiometry (DXA) (QDR1000,Hologic,
Waltham, MA) and have been previously described as well9.
STATISTICAL ANALYSIS
Differences in subject characteristics and BMD variables
between RHOA cases and participants without RHOA were
assessed by Student’s t test for continuous variables and
Chi-square tests for dichotomous variables. HardyeWein-
berg equilibrium was assessed in both groups by Chi-
square tests, and allele frequencies were calculated using
the gene counting method. Logistic regression was used
to estimate odds ratios (ORs) and 95% conﬁdence intervals
(CI) for each genotype (for Pvu II TT, TC and CC; for Xba I
AA, AG, GG) and the risk of any RHOA, RHOA deﬁned by
JSN 3 or RHOA deﬁned by femoral osteophytosis of 2,
and incident RHOA. All analyses for the association of
ESR1 Pvu II (C/C and C/T) and Xba I (G/G and G/A) geno-
types and RHOA deﬁnitions were performed both with and
without adjustments for known and potentially confounding
variables including age, height, weight, estrogen use, and
femoral neck BMD. Statistical analysis was performed using
the statistical software program SAS version 8.2 (SAS Insti-
tute, Inc., Cary, NC).
Results
CHARACTERISTICS OF STUDY SUBJECTS
AND GENOTYPE FREQUENCIES
Among the 4703 study subjects, 569 satisﬁed the criteria
for RHOA, of which 325 subjects had JSN grade 3, and
130 had moderate to severe osteophytes (Fig. 1). When
compared with the 4134 control subjects who did not satisfy
the RHOA criteria, the RHOA cases were older, poorer
overall health status, and had higher femoral neck BMD
(Table I). All other subject characteristics and BMD vari-
ables were not signiﬁcantly different between the two
groups. The frequency of the Pvu II C allele in the cohort
was 21.1%, and the frequency of the Xba I G allele in the
cohort was 11.8% and both were similar to frequencies ob-
served in similar populations15e17. Genotype frequencies
did not deviate from HardyeWeinberg equilibrium.
ORs FOR PREVALENT RHOA
There was nearly a 30% reduction in the odds of RHOA
between the C/C genotype when compared to the T/T ge-
notype at the Pvu II site (P< 0.01) (Table II). Adjustment
for age, weight, height, femoral neck BMD, and estrogen
use did not alter this association between the C/C geno-
type and reduced RHOA (P< 0.01). A similar reduction
was observed with the RHOA phenotype characterized
by moderate to severe JSN with reduced odds of nearly
35% (P< 0.01) for the C/C genotype compared to the
T/T, and this remained after adjustment for covariates.
There was also a ‘‘dose response’’ with each copy of the
C allele and Pvu II, although this association was not sig-
niﬁcant. No association was observed for the Pvu II geno-
type and RHOA characterized by moderate to severe
osteophytosis.
There was an inverse association observed between the
Xba I G/G or G/A genotypes and RHOA when compared to
975Osteoarthritis and Cartilage Vol. 15, No. 8the A/A genotype (Table III), although it did not reach statis-
tical signiﬁcance.
INCIDENT RHOA
There were 2451 subjects who had no RHOA at the
baseline visit and 305 who developed incident RHOA at
the follow-up visit. Subjects with the Pvu II C/C genotype
had a reduced risk of incident RHOA, of nearly 25% com-
pared to those with the T/T genotype but this difference
was not signiﬁcant (P¼ 0.11). However, subjects with the
Pvu II C/C genotype who were on estrogen during the fol-
low-up period (n¼ 452) had over a 30% reduction in risk
Table I
Subject characteristics with RHOA and controls at visit 5
Characteristic RHOA cases Controls P value
Number 569 4134 e
Age (years) 79.6 5.0 78.4 4.6 <0.01
Height (cm) 157.6 6.3 157.7 6.2 0.60
Weight (kg) 66.3 12.8 66.2 12.8 0.84
BMI (kg/m2) 26.7 5.0 26.6 4.8 0.48
Age at menopause
(years)
48.4 5.4 48.2 5.6 0.63
Current estrogen
use (%)
17.4 19.1 0.34
Current vitamin D
use (%)
48.2 47.9 0.91
Smoking (%) 4.4 4.8 0.64
Health status,
good/excellent (%)
73.6 81.3 <0.01
Areal BMD by DXA (g/cm2)
Total hip 0.74 0.13 0.73 0.14 0.53
Femoral neck 0.67 0.14 0.62 0.11 <0.01
Genotype frequencies
Pvu II
TT (%) 188 (33.2) 1162 (28.3) 0.03
TC (%) 277 (48.9) 2067 (50.3)
CC (%) 102 (18.0) 884 (21.5)
Xba I
AA (%) 257 (45.2) 1700 (41.2) 0.20
AG (%) 250 (43.9) 1932 (46.9)
GG (%) 62 (10.9) 491 (11.9)
Continuous values are noted in meanSD, dichotomous values
noted as percentage. P values are from Chi-square test for dichot-
omous variables and from Student’s t test for continuous variables.of incident RHOA compared to subjects with T/T genotype
(n¼ 584) (P< 0.05) (Table IV). The interaction of prior es-
trogen use and Pvu II genotype age-adjusted was
P¼ 0.73 and for Xba I P¼ 0.39.
Discussion
The present study addressed the association between
polymorphisms of ESR1 and the risk of RHOA. We found
that ESR1 Pvu II SNP (C/C) was associated with reduced
prevalence of RHOA and incidence of RHOA by nearly
30%. The reduced odds of prevalent RHOA was most sig-
niﬁcant in the subgroup of RHOA subjects with moderate
to severe JSN. Since radiographic evidence of JSN is a sur-
rogate marker for loss of articular cartilage, this polymor-
phism may protect against cartilage loss. Interestingly,
there was no association with the Xba I SNP and RHOA
in this population. Lastly, we report that subjects with the
Pvu II C/C genotype on estrogen treatment have a modest
but signiﬁcant reduction in the development of incident
RHOA compared to subjects without this genotype.
This may be the ﬁrst study to ﬁnd a reduced risk of RHOA
with the ESR1 Pvu II polymorphism. Ushiyama et al. re-
ported an increased risk of generalized OA with the Pvu II
and Xba I minor genotypes present with 65 OA patients
and 318 controls16, and Loughlin et al.19 found no increased
risk of idiopathic OA of the hip and knee with the same
ESR1 SNPs with 371 OA patients and 369 controls. Bergink
et al. reported an increased risk of knee OA with Pvu II and
Xba I polymorphisms with an OR of 2.2 for homozygotes
(Pvu II C/C) and especially for the subgroup of knee OA
subjects with osteophytes as the primary radiographic
feature17.
There have been reports that the polymorphisms of the
ESR1 are associated with differences in BMD20,21. Indeed,
Bergink et al. found a relationship between osteophytes and
increased risk of knee OA with ESR1 Pvu II and Xba I poly-
morphisms17. They further hypothesized that variations in
the ESR1 may be associated with changes in juxtaarticular
bone or its response to external forces, rather than articular
cartilage and this might lead to more severe OA later in
life17. Interestingly, our group has reported that hip BMD
is associated with RHOA in this cohort; however, adjust-
ment for femoral neck BMD did not alter the inﬂuence of
the Pvu II C/C genotype to reduce the risk of RHOA in
our study.Table II
Association between ER alpha (Pvu II) and RHOA status
Cases/Total (%) OR (95% CI)* OR (95% CI)y
RHOA 567/4680 (12.1) e e
TT 188/1350 (13.9) 1.0 (ref) 1.0 (ref)
TC 277/2344 (11.8) 0.84 (0.69, 1.03) 0.87 (0.71, 1.08)
CC 102/986 (10.3) 0.71 (0.55, 0.92) 0.71 (0.54, 0.94)
Osteophytosis 130/4243 (3.1) e e
TT 40/1202 (3.3) 1.0 (ref) 1.0 (ref)
TC 65/2132 (3.1) 0.92 (0.62, 1.38) 0.93 (0.62, 1.41)
CC 25/909 (2.8) 0.82 (0.49, 1.36) 0.85 (0.50, 1.42)
JSN 324/4437 (7.3) e e
TT 111/1273 (8.7) 1.0 (ref) 1.0 (ref)
TC 158/2225 (7.1) 0.82 (0.63, 1.05) 0.86 (0.65, 1.13)
CC 55/939 (5.9) 0.65 (0.46, 0.91) 0.67 (0.46, 0.96)
*Age-adjusted.
yAdjusted for age, weight, height, ERT use, femoral neck BMD.
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Association between ER alpha (Xba I) and RHOA status
Cases/Total (%) OR (95% CI)* OR (95% CI)y
RHOA 569/4692 (12.1) e e
AA 257/1957 (13.1) 1.0 (ref) 1.0 (ref)
AG 250/2182 (11.5) 0.87 (0.72, 1.05) 0.88 (0.73, 1.08)
GG 62/553 (11.2) 0.82 (0.61, 1.10) 0.77 (0.56, 1.05)
Osteophytosis 130/4253 (3.1) e e
AA 52/1752 (3.0) 1.0 (ref) 1.0 (ref)
AG 65/1997 (3.3) 1.11 (0.77, 1.61) 1.16 (0.79, 1.69)
GG 13/504 (2.6) 0.86 (0.46, 1.59) 0.85 (0.46, 1.60)
JSN 325/4448 (7.3) e e
AA 153/1853 (8.3) 1.0 (ref) 1.0 (ref)
AG 137/2069 (6.6) 0.80 (0.63, 1.02) 0.79 (0.61, 1.03)
GG 35/526 (6.7) 0.78 (0.53, 1.14) 0.72 (0.47, 1.09)
*Age-adjusted.
yAdjusted for age, weight, height, ERT use, femoral neck BMD.Our observation of a reduced risk of RHOA with ESR1
Pvu II polymorphism was associated with the protection of
loss of joint space, a radiographic surrogate for articular car-
tilage. As this ER is found on articular chondrocytes it may
be that this polymorphism may be associated with en-
hanced transcriptional activity or this polymorphism may
be in linkage disequilibrium with a functional polymorphism
at another location within the ESR1 gene region9,10. Alter-
natively, subjects with the C allele of ESR1 may develop
more articular cartilage than those without it. However, we
did not ﬁnd a signiﬁcant difference in articular minimal joint
space width, a surrogate measure for the amount of articu-
lar cartilage in subjects with the C allele of Pvu II compared
to the T/T genotype in our study population.
Since epidemiologic studies report hormone replacement
therapy reduce the incidence of hip OA13, we evaluated if
the development of incident RHOA in subjects with the
ESR1 Pvu II polymorphism (C/C vs T/T or C/T) was inﬂu-
enced by ERT. The risk of incident RHOA was reduced
about 25% in the subjects with the Pvu II C/C vs T/T geno-
type overall, but ERT reduced the risk to greater than 30%
in C/C vs T/T subjects. Other investigators have found that
women on ERT with the Pvu II C allele had more protection
against fracture risk than the T/T group28. Also, mesenchy-
mal-stem cell derived osteoblasts (MSCOs) obtained from
individuals with the C allele of ESR1 had a higher basal dif-
ferentiation capacity of these MSCOs than individuals with-
out the C allele, however those with the C allele had higher
response to sex steroid treatment. These results could as-
sist in explaining the contradictory effects of ERT on osteo-
blasts in vitro and in vivo and also help to explain the
different responses to ERT29.In addition, Herrington et al. found women with the Pvu II
polymorphism of ESR1 had a greater increase in high den-
sity lipoprotein (HDL) and greater reduction in E-selectin,
a soluble adhesion molecule involved in inﬂammation, on
ERT30,31. These investigators went on to determine
whether this intronic SNP had some functional signiﬁcance
and found the C allele produced a favorable and function-
ally signiﬁcant binding site for the myb transcription factor.
To date there are no data that this genotype is not the func-
tional polymorphism responsible for the observed differen-
tial responses. Nonetheless, it could be that this
polymorphism is in linkage disequilibrium with another poly-
morphism that is the functional variant32. In addition, if OA is
a chronic low grade inﬂammatory disease33, then the mod-
est reduction in systemic inﬂammation, e.g., reduced E-
selectin levels, in subjects on ERT and with the Pvu II C al-
lele might be the pathway in which these subjects either de-
velop less or have slower RHOA disease progression30.
Additional studies are needed to elucidate these ﬁndings.
This study offers several strengths, including its large
community-based cohort of elderly Caucasian women and
a validated radiographic scoring system that allowed for
the construction of phenotype-speciﬁc deﬁnitions to fully
characterize the extent of RHOA. However, there are also
several potential limitations. Our radiographic deﬁnitions of
RHOA may not be comparable to other grading schemes.
Also, despite the large number of subjects with DNA and
a hip radiograph available for scoring OA, we only had
569 subjects with RHOA and the numbers of participants
were smaller when we subdivided by either genotype, indi-
vidual radiographic features or disease progression. How-
ever, with our study sample size we had over 90% powerTable IV
Association between ER alpha (Pvu II) and incident RHOA on and off ERT
ERT No ERT
Cases/Total (%) OR (95% CI)* OR (95% CI)y Cases/Total (%) OR (95% CI)* OR (95%CI)y
RHOA 254/2136 (11.9) e e 305/2451 (12.4) e e
TT 81/584 (13.9) 1.0 (ref) 1.0 (ref) 104/737 (14.1) 1.0 (ref) 1.0 (ref)
TC 128/1100 (11.6) 0.82 (0.61, 1.10) 0.81 (0.59, 1.12) 144/1199 (12.0) 0.85 (0.65, 1.12) 0.91 (0.68, 1.21)
CC 45/452 (10.0) 0.68 (0.46, 1.01) 0.66 (0.44, 0.99)þ 57/515 (11.1) 0.75 (0.53, 1.06) 0.78 (0.54, 1.13)
þP< 0.05.
*Age-adjusted.
yAdjusted for age, weight, height, femoral neck BMD.
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ease and greater than 80% for incident disease. This study
population was limited to Caucasian women aged 65 years
and older and we only evaluated one anatomic site for OA.
Our ﬁndings may not be generalized to other populations or
to other anatomic sites for OA such as the knee and the
hand. Also, population stratiﬁcation is an often cited limita-
tion of candidate gene studies because population stratiﬁ-
cation can contribute to false-positive associations and an
inability to reproduce ﬁndings34. Women in the present
study were recruited from several clinical centers in the
United States and any resultant population stratiﬁcation
could have in principle produced false-positive results.
However, adjusting for study center and northern European
ancestry had no effect on our ﬁndings.
In summary, we found that the Pvu II C/C genotype of the
ESR1 was associated with a modestly reduced risk of prev-
alent and incident RHOA. Our ﬁndings differ from those re-
ported for this polymorphism in knee OA and generalized
OA in other populations. Additional work is now required
to determine why this polymorphism prevents RHOA
development.
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